Navigation Links
TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
Date:11/12/2008

LA JOLLA, Calif., Nov. 12 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that the Board of Directors has appointed Evelyn Graham as the Company's Chief Executive Officer and as a member of the Company's Board of Directors. Ms. Graham had been serving as the Company's acting Chief Executive Officer since September 1, 2008.

"Ev has done an impressive job as acting CEO in managing the transition of our company and building a platform for the future," said Peter Davis, Chairman of the TorreyPines Board of Directors. "We are delighted that she has agreed to become CEO and a member of the Board at a time when TorreyPines is completing important clinical trials that hold promise for the company's future. With her considerable drug development experience as well as global senior management roles, she has the right mix of skills and experience to successfully lead the Company in meeting its strategic objectives."

"I am excited by this opportunity and look forward to continuing to work with TorreyPines' talented management team and dedicated employees," said Ms. Graham.

Ms. Graham joined TorreyPines in 2004 as Vice President, Development. She was then promoted to Vice President, Corporate Development in 2005, Chief Operating Officer in 2006 and acting Chief Executive Officer in September 2008. Prior to joining TorreyPines Ms. Graham was Executive Director, Development Operations at Purdue Pharma from 2000 to 2003. From 1998 to 2000, she was Senior Vice President of Business Development at Ingenix Pharmaceutical Services, a division of UHG, and served as Vice President of Clinical Operations at Worldwide Clinical Trials, prior to its acquisition by UHG. Previously, Ms. Graham held positions in oper
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
2. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
5. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
6. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
7. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
8. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
11. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , SANTA CRUZ, Calif., Nov. 24 /PRNewswire/ ...io Career Center, the nation,s leading online job ...als. ,, Northwestern and Columbia University ar...ajor life science training Institutions. ,, The... post-graduates in the life sciences. While there ...
(Date:11/24/2009)... , REYKJAVIK, Iceland, November.... (Nasdaq: DCGN ) today announced that it has rece...ing in the company,s common stock will be,suspende...e filed with the,Securities and Exchange Commissio...sting on Nasdaq, unless the company files an appea...
(Date:11/24/2009)... Health care employment grew b...e only one to show consistent growth during the U....tals remain in trouble, and health systems are com...nnel, instead of just administrators. , ... care employment continued growing in October desp...
(Date:11/24/2009)... , SHANGHAI, Nov. 24 /PRNewswire-Asia/ --...& Trademark Office (PTO) has allowed the paten...or NOD technology. , NOD technology is a ...or,proteins into bio-adhesive nano-particles to en... as injections. NOD technology is a platform techn...
Breaking Biology Technology:Two Major Universities Join Nation's Leading Postgrad Bio Job Board 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4
... 26 Joseph F. Finn, Jr., C.P.A. ("Finn"), announc...erest from pharma companies in the intellectual pr.... , , In preclinical studies, GCS-100 inhibited b...s. Development and growth of solid tumors require...iver oxygen and nutrients to a tumor. Galectin-3 ...
...outstanding, world-changing leaders to participate...s of the TED Conference introduced today the 25 ne... international conference, TEDGlobal. These Fellow...ttending TEDGlobal 2009, to be held in Oxford, UK,...TED Fellows selected for the TED2009 Conference, h...
...ornia and AMSTERDAM, May 26 ,Agendia, a world lead...d the,opening of its U.S. clinical genomics labora...lly-licensed and compliant with the Clinical Labor...ed by the Centers for Medicare,and Medicaid Servic...ncer genomics laboratory, Agendia has,over the pas...
Other Biology Technology:Prospect Therapeutics, Inc.'s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models 2TED Conferences Announces 25 TED Fellows for TEDGlobal in Oxford 2TED Conferences Announces 25 TED Fellows for TEDGlobal in Oxford 3TED Conferences Announces 25 TED Fellows for TEDGlobal in Oxford 4TED Conferences Announces 25 TED Fellows for TEDGlobal in Oxford 5Agendia Opens CLIA-Registered U.S. Genomics Laboratory 2Agendia Opens CLIA-Registered U.S. Genomics Laboratory 3
(Date:11/25/2009)...Head of the Cell Death Research Laboratory in the ...een awarded the prestigious Johnson & Johnson Focu...ause of brain cell damage in Parkinson,s disease. ...s in support of innovation and excellence in scien...d earlier this month at an event at the Hyatt Rege...
(Date:11/24/2009)...s it has been prescribed by traditional healers in...s and stomach pain to fever and flu. , Now for th...have been able to scientifically prove the pain re...known as Brazilian mint. , Testing this ancient S...cher Graciela Rocha was able to show that when pre...
(Date:11/24/2009)...on of a remarkable class of ring-shaped protein mo...wrence Berkeley National Laboratory (Berkeley Lab)...beamline at the Advanced Light Source (ALS). These...ion and replication, and are vital to the survival...ents, such as the human papillomavirus, which has ...
Breaking Biology News(10 mins):Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Got a pain? -- Have a cup of Brazilian mint 2Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 14702 1Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 14702 2Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 14702 3Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 14702 4Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 14702 5Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 14702 6Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update 14702 7Cancer Diagnostics Company On Q ity Raises 2421M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy 5961 1Cancer Diagnostics Company On Q ity Raises 2421M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy 5961 2Varian Inc to Release Fourth Quarter and Full Fiscal Year 2009 Financial Results 5957 1
...searchers at NYU Langone Medical Center may have d...ndrome (BTHS). BTHS, a sometimes fatal disease, is...y in males that leads to infection or heart failur...alcium-independent phospholipase A2 in the pathoge...n the Proceedings of the National Academy of Scie...
...N ARBOR, Mich. Researchers from the University of...ied a gene that is overexpressed in 90 percent of .... , Expression of the gene, Ataxia Telangiectasia...erage 20 times higher in pancreatic cancer cells t...the gene appears to make pancreatic cancer cells r...
... international team of scientists, led by Monash U...of a superbug that kills elderly hospital patients... save lives and health care systems billions of do...n the prestigious scientific journal Nature , unr...Clostridium difficile and solved the mystery surr...
Other Biology News:New potential therapeutic target discovered for genetic disorder -- Barth syndrome 2U-M researchers ID gene involved in pancreatic cancer 2Monash scientists debug superbug 2
... fluorescent nucleic acid dye which binds only to ...erstain, propidium iodide stains the nucleus light...provides excellent contrast to green or blue fluor...ide can be used for fluorescent in situ hybridizat...
...ter assay for mitochondrial membrane potential det...are detected by carboxyfluorescein (FAM)-labelled ... are cell-permeable, non-cytotoxic and bind covale...he same time the mitochondrial membrane potential ...
...tured in DMEM and harvested at the log phase of gr...ve forms, cells were fixed in acetone-methanol. T...coated slide, with each wells surface specifically...imize background staining. Each well is loaded wi...
...r can be induced prior to DNA purification increas...y of single-copy BACs with the high yields associa...s provide the linearized vector and associated rea...stem) necessary to create a 10X human BAC library....
Biology Products: